Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following statements is false regarding intracellular receptors?

They are the fastest acting receptors.. ***They are the fastest acting receptors.*** - Intracellular receptors regulate gene expression and protein synthesis, which is a **slow process** taking hours or days to manifest effects. - Receptors like **ligand-gated ion channels** are the fastest acting, producing effects within milliseconds due to direct ion flow. *Act by regulating gene expression* - Intracellular receptors, such as **steroid hormone receptors**, typically bind to their ligands within the cytoplasm or nucleus. - This binding leads to their translocation to the nucleus (if not already there), where they act as **transcription factors** to regulate gene expression. *Glucocorticoid receptors are a type of intracellular receptor.* - **Glucocorticoids** are **lipid-soluble hormones** that can readily cross the cell membrane. - They bind to specific intracellular receptors in the cytoplasm, forming a hormone-receptor complex that then translocates to the nucleus. *DNA contains hormone responsive elements.* - Once the activated intracellular hormone-receptor complex enters the nucleus, it binds to specific sequences on the DNA called **hormone responsive elements (HREs)**. - This binding initiates or represses the transcription of target genes, leading to changes in **protein synthesis**.

Q: What is the role of oxidation in biotransformation?

Functionalization reaction. ***Functionalization reaction*** - Oxidation is a **Phase I biotransformation reaction**, which primarily involves introducing or exposing a functional group (like hydroxyl, carboxyl, amine) on the parent compound. - This makes the molecule more **polar** and often more reactive, preparing it for subsequent Phase II (conjugation) reactions. *Conjugation reaction* - Conjugation reactions are **Phase II biotransformation reactions**, which involve the covalent attachment of a large, highly polar, endogenous molecule (e.g., glucuronic acid, sulfate, glutathione) to the functional group created during Phase I. - Their main role is to further increase **water solubility** and facilitate **excretion**, rather than introducing functional groups. *Synthetic reaction* - The term "synthetic reaction" is a general chemical term and not a specific, commonly used classification for biotransformation phases in pharmacology. - While biotransformation involves chemical synthesis within the body, this term does not accurately describe the specific role of oxidation in drug metabolism. *Felson reaction* - The "Felson reaction" is **not a recognized term** in the context of biotransformation or drug metabolism. - This option is a distracter and does not correspond to any known biochemical process.

Q: Glucuronidation takes place in?

Liver. ***Liver*** - The **liver** is the primary organ responsible for **glucuronidation**, a crucial phase II detoxification pathway [1]. - This process conjugates **glucuronic acid** with various endogenous and exogenous substances, making them more water-soluble for excretion [1]. *RBC* - **Red blood cells (RBCs)** primarily function in **oxygen transport** and lack the extensive metabolic machinery for glucuronidation. - While they possess some enzymatic activities, detoxification pathways like glucuronidation are not a significant function. *Pancreas* - The **pancreas** is mainly involved in producing **digestive enzymes** and **hormones** (insulin, glucagon) for blood glucose regulation. - It does not play a direct role in drug or toxin metabolism through processes like glucuronidation. *Thyroid* - The **thyroid gland** is responsible for producing **thyroid hormones** that regulate metabolism. - Its metabolic activity is distinct from the detoxification functions performed by the liver, and it does not perform glucuronidation.

Q: Most variable absorption is seen with which route?

Oral. ***Oral*** - **Oral absorption** is highly variable due to numerous factors, including stomach pH, presence of food, drug formulation, and individual patient differences in gastrointestinal motility and enzyme activity [1], [3]. - The drug must first dissolve and then pass through the **intestinal wall** into the bloodstream, where it is also subject to **first-pass metabolism** in the liver, all contributing to variability [2]. *Intramuscular* - While generally reliable, **intramuscular absorption** can vary depending on factors such as muscle blood flow, which can be influenced by activity, temperature, and depth of injection. - However, it bypasses the harsh gastrointestinal environment and has less intrinsic variability than oral administration. *Intravenous* - **Intravenous administration** provides the most direct and complete absorption, as the drug is introduced directly into the bloodstream, bypassing all absorption barriers. - Therefore, it exhibits **no variability in absorption** (bioavailability is 100%), making this option incorrect [4]. *Per rectal* - **Rectal absorption** can be variable, as it depends on factors like the drug's lipid solubility, the pH of the rectal fluid, and the presence of fecal matter. - However, it typically avoids **first-pass metabolism** to some extent and often provides more predictable absorption than oral routes, especially for drugs irritating to the stomach.

Q: Which of the following drug substrate combinations is incorrectly matched?

CYP 2C8/9 - mifepristone. ***CYP 2C8/9 - mifepristone*** - **Mifepristone** is primarily metabolized by **CYP 3A4**, not CYP 2C8/9. - CYP 2C8/9 metabolizes drugs like **warfarin**, rosiglitazone, and tolbutamide. *CYP 3A4/5 - simvastatin* - **Simvastatin** is a known substrate for **CYP 3A4/5**, and its metabolism can be significantly affected by CYP 3A4/5 inhibitors or inducers. - This interaction is clinically important for **drug-drug interactions** concerning statin therapy. *CYP 2D6 - SSRI* - Many **Selective Serotonin Reuptake Inhibitors (SSRIs)**, such as fluoxetine, paroxetine, and venlafaxine, are metabolized by **CYP 2D6**. - This makes CYP 2D6 a crucial enzyme in determining **SSRI efficacy** and **side effect profiles**. *CYP 2C19 - omeprazole* - **Omeprazole**, a proton pump inhibitor, is primarily metabolized by **CYP 2C19** and also by CYP 3A4. - Genetic polymorphisms in **CYP 2C19** can significantly affect omeprazole's metabolism and clinical efficacy.

Q: Which of the following is NOT an advantage of sustained release preparations over conventional preparations?

Drugs with very long half-life are suitable. ***Drugs with very long half-life are suitable*** - Sustained-release preparations are most suitable for drugs with a **half-life between 2 to 8 hours** (some sources suggest 3-12 hours). - Drugs with a **very long half-life (>12-24 hours)** are already long-acting enough that a sustained-release formulation offers **little to no additional benefit**. - Such drugs already maintain therapeutic levels for extended periods without the need for special formulation. - Formulating a drug with a very long half-life into a sustained-release form could lead to **excessive accumulation** and make dose adjustments difficult. - Therefore, suitability of drugs with very long half-life is **NOT an advantage** - it's actually a limitation of sustained-release technology. *Decreased frequency of administration* - This is a primary advantage of sustained release, as it allows for **less frequent dosing intervals** (e.g., once or twice daily instead of multiple times a day). - Reduced dosing frequency helps maintain **therapeutic drug levels** over a longer period without repeated administration. *Improved compliance* - Less frequent dosing directly contributes to **better patient adherence** to the medication regimen. - Patients are more likely to take their medication as prescribed when the **dosing schedule is simpler and less demanding**. *Less incidence of high peak side effects* - Sustained-release formulations provide a **slow and continuous drug release**, avoiding the rapid absorption and high plasma peaks seen with conventional formulations. - This smoother plasma concentration profile leads to **fewer dose-related side effects** associated with high peak drug concentrations.

Q: Which of the following is the longest acting oral anticoagulant?

Bishydroxycoumarin. ***Bishydroxycoumarin*** - **Bishydroxycoumarin** (dicoumarol) has a very long duration of action, with effects lasting up to 2-10 days after a single dose due to its slow metabolism and excretion. - Its prolonged action and unpredictable anticoagulant response have led to it being largely replaced by other oral anticoagulants like **warfarin** in clinical practice. *Warfarin* - **Warfarin** has a half-life of approximately 36-42 hours, leading to an anticoagulant effect that lasts for about 2-5 days after discontinuation. - It is a widely used oral anticoagulant, but its duration of action is significantly shorter than that of bishydroxycoumarin. *Acenocoumarol* - **Acenocoumarol** has a relatively short half-life of about 8-11 hours, and its anticoagulant effects typically dissipate within 1-2 days after discontinuation. - It is often preferred in situations where a rapid reversal of anticoagulation might be necessary, due to its shorter duration of action compared to warfarin. *Phenindione* - **Phenindione** is an indandione derivative, a class of oral anticoagulants, with a duration of action of approximately 2-4 days. - It is rarely used now due to a higher incidence of adverse effects, including hypersensitivity reactions and hematological toxicities, compared to coumarin derivatives.

Q: A young child weighing 20 kg is administered a drug at a dose of 100 mg/kg body weight. Given that the plasma concentration of the drug is 2 mg/dL and the clearance is 13,860 mL/hr, calculate the time required to reach steady state plasma concentration.

30 hours. ***30 hours*** - To reach **steady-state concentration**, approximately **5 half-lives (t½)** are required, at which point the drug reaches ~97% of steady state. - First, calculate the **volume of distribution (Vd)**: Total dose = 100 mg/kg × 20 kg = 2000 mg. Plasma concentration = 2 mg/dL = 20 mg/L. Therefore, **Vd = Dose/Cp = 2000 mg / 20 mg/L = 100 L**. - Next, calculate the **half-life (t½)** using the formula: **t½ = 0.693 × Vd / Cl**. Given **Clearance (Cl)** = 13,860 mL/hr = 13.86 L/hr, we get **t½ = (0.693 × 100 L) / 13.86 L/hr = 5 hours**. - Time to reach steady state = **5 × t½ = 5 × 5 hours = 25 hours**. While the calculated value is 25 hours, **30 hours (6 half-lives)** is the closest option and ensures steady state is definitively reached, as clinical practice often considers 4-6 half-lives as the range for steady state. *20 hours* - This duration represents only **4 half-lives**, which achieves approximately **94% of steady-state** concentration. - While close, this is slightly **premature** compared to the standard 5 half-lives required for steady state, and is further from the calculated 25 hours than the correct answer. *10 hours* - This duration represents only **2 half-lives**, which is **insufficient to reach steady-state** plasma concentration. - At 10 hours, the drug concentration would only be around **75% of steady-state**, not fully accumulated. *40 hours* - This duration represents **8 half-lives**, which is **excessively long** for achieving steady-state. - By this point, the drug would have been at **steady-state for several half-lives**, making this an unnecessarily prolonged estimate.

Q: Most common enzyme for drug metabolism and detoxification reactions?

CYP3A4. ***CYP3A4*** - **CYP3A4** is the most abundant and versatile **cytochrome P450 enzyme** in the human liver and intestine, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its broad substrate specificity and high expression levels make it a critical player in **drug detoxification** and metabolism. *CYP1A2* - While important, **CYP1A2** is primarily involved in the metabolism of only about **10% of therapeutic drugs** and specific endogenous compounds. - It plays a significant role in the metabolism of **caffeine** and some **polycyclic aromatic hydrocarbons**, but its overall contribution to drug metabolism is less than that of CYP3A4. *CYP2A6* - **CYP2A6** is a minor **cytochrome P450 enzyme** that metabolizes a limited number of drugs and xenobiotics. - Its primary role is in the metabolism of **nicotine** and certain **tobacco-specific nitrosamines**, making it less globally significant for general drug detoxification compared to CYP3A4. *CYP2B6* - **CYP2B6** metabolizes a relatively small fraction of drugs, around **3% to 5%** of those currently in clinical use. - While it is important for the metabolism of some **antiretrovirals** and **antidepressants**, its contribution to overall drug metabolism and detoxification is considerably less extensive than that of CYP3A4.

Q: Refer to the graph showing three drugs A, B, and C. Which of the following drugs has the highest potency?

Drug A. ***Drug A*** - **Potency** refers to the amount of drug needed to produce a given effect; a drug with higher potency produces a greater effect at lower concentrations. - **Drug A** achieves its peak effect at the lowest concentration among the three, indicating it is the most potent. *Drug B* - **Drug B** reaches an intermediate peak effect at significantly higher concentrations compared to Drug A. - Its curve is shifted to the right of Drug A, indicating lower potency than Drug A. *Drug C* - **Drug C** requires the highest concentration to achieve its maximum effect, and also has the lowest maximum effect compared to Drugs A and B. - This indicates it has the lowest potency and efficacy of the three. *Both Drug A and B* - While both drugs exhibit efficacy, **Drug A** is distinctly more potent than Drug B, as it achieves its maximum effect at a much lower concentration. - Therefore, stating both have the highest potency is incorrect because Drug A is clearly superior in potency.

Question 1

Which of the following statements is false regarding intracellular receptors?

Accepted Answer

They are the fastest acting receptors.

Answer

Act by regulating gene expression

Answer

Glucocorticoid receptors are a type of intracellular receptor.

Answer

DNA contains hormone responsive elements.

Question 2

What is the role of oxidation in biotransformation?

Accepted Answer

Functionalization reaction

Answer

Conjugation reaction

Answer

Synthetic reaction

Answer

Felson reaction

Question 3

Glucuronidation takes place in?

Accepted Answer

Liver

Answer

RBC

Answer

Pancreas

Answer

Thyroid

Question 4

Most variable absorption is seen with which route?

Accepted Answer

Oral

Answer

Intravenous

Answer

Per rectal

Answer

Intramuscular

Question 5

Which of the following drug substrate combinations is incorrectly matched?

Accepted Answer

CYP 2C8/9 - mifepristone

Answer

CYP 3A4/5 - simvastatin

Answer

CYP 2D6 - SSRI

Answer

CYP 2C19 - omeprazole

Question 6

Which of the following is NOT an advantage of sustained release preparations over conventional preparations?

Accepted Answer

Drugs with very long half-life are suitable

Answer

Improved compliance

Answer

Less incidence of high peak side effects

Answer

Decreased frequency of administration

Question 7

Which of the following is the longest acting oral anticoagulant?

Accepted Answer

Bishydroxycoumarin

Answer

Warfarin

Answer

Acenocoumarol

Answer

Phenindione

Question 8

A young child weighing 20 kg is administered a drug at a dose of 100 mg/kg body weight. Given that the plasma concentration of the drug is 2 mg/dL and the clearance is 13,860 mL/hr, calculate the time required to reach steady state plasma concentration.

Accepted Answer

30 hours

Answer

20 hours

Answer

10 hours

Answer

40 hours

Question 9

Most common enzyme for drug metabolism and detoxification reactions?

Accepted Answer

CYP3A4

Answer

CYP1A2

Answer

CYP2A6

Answer

CYP2B6

Question 10

Refer to the graph showing three drugs A, B, and C. Which of the following drugs has the highest potency?

Accepted Answer

Drug A

Answer

Drug B

Answer

Drug C

Answer

Both Drug A and B

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?